Based in Munich, Germany, TRCE is strategically located within a vibrant biotech cluster, and benefits from close proximity to a dynamic network of innovation, promoting collaboration and knowledge exchange. The center maintains strong partnerships with leading scientific organizations, contract research organizations (CROs), and academic institutions, facilitating access to cutting-edge technologies, extensive expertise, and high-quality research capabilities. TRCE maintains strong collaborative ties with its R&D center in Tokyo, as well as with its research partners in DSI. These partnerships enable continuous knowledge sharing and the exchange of technical expertise, methodologies, and best practices across locations. Such collaborations foster a dynamic research environment, enhancing TRCE‘s ability to translate scientific insights into practical applications that support the research development pipeline.
To reduce reliance on traditional preclinical testing approaches, advanced tissue-based model systems have become increasingly important in driving progress in biomedical science. Our scientific team works with in vitro models derived from clinically relevant sources, enabling insights that more closely reflect real patient biology and architecture. This strengthens the ability to make more reliable predictions about the efficacy and safety of emerging therapies.
Our researchers have extensive experience working with biological samples to better understand complex disease mechanisms. By applying state-of-the-art technologies, we generate detailed molecular insights that help clarify how diseases develop and progress. This knowledge supports the design of more precise and effective therapeutic strategies tailored to specific biological pathways.
By harnessing clinical relevance, TRCE bridges the gap between early-stage discovery and real-world patient data, increasing the likelihood that research findings translate into meaningful clinical outcomes. In addition, we actively collaborate with leading scientific institutions - across both academia and industry, within Europe and internationally - to strengthen our Research and Development capabilities, foster innovation, and accelerate the advancement of next-generation therapies.
More Stories
Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other…
Our ratio of R&D expenses to revenues is > 20% globally.
